Treating Patients With Metastatic or Recurrent Cervical Cancer Post Chemotherapy

In the first article of a 2-part series, Shannon N. Westin, MD, MPH, looks at the promising responses to tisotumab vedotin for patients with recurrent or metastatic cervical cancer.

Susan C. Modesitt, MD, discusses the introduction of antibody drug conjugate tisotumab vedotin to treatment for patients with metastatic cervical cancer.